Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15450545 | 0.81 | POLB (0.61) | SMN1; SMN2TSHRALDH1A1POLBGAA | |
| SCHEMBL433417 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL433389 | 0.80 | SMN1; SMN2 (0.60) | SMN1; SMN2TSHRPOLB | |
| SCHEMBL13970042 | 0.77 | ITGB3 (0.55) | ALDH1A1TACR1 | |
| SCHEMBL13205568 | 0.77 | ALDH1A1 (0.61) | EGFRALDH1A1TACR1POLBTP53 | |
| SCHEMBL731514 | 0.77 | ITGB3 (0.52) | ALDH1A1 | |
| SCHEMBL27515952 | 0.76 | POLB (0.54) | TSHRALDH1A1TACR1POLBTP53 | |
| SCHEMBL13960043 | 0.76 | TACR1 (0.49) | TSHRALDH1A1TACR1POLBATM | |
| SCHEMBL1628974 | 0.75 | TP53 (0.52) | EGFRALDH1A1TACR1POLBTP53 | |
| SCHEMBL9405476 | 0.75 | TP53 (0.52) | EGFRALDH1A1TACR1POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595994-B1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| EP-2595994-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | Glaxo Group Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2012012391-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | DHPS, AKR1C3, Q6ZSR9 | SMN1; SMN2 4213/4885TSHR 1193/4885EGFR 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.